Thalidomide Off-Label Coverage
This article was originally published in The Pink Sheet Daily
Executive Summary
"I think we are making a lot of progress" in working with CMS to gain coverage for thalidomide for cancer in the demonstration project under Medicare Part B, Sen. Kay Bailey Hutchison (R-Tex.) tells the Blood Cancer Coalition May 19 during its "advocacy day" luncheon on Capitol Hill
You may also be interested in...
CMS Off-Label Cancer Drug Policy Will Have "Very Narrow" Focus
Policy decision for covering unapproved, non-compendial indications for cancer drugs is still pending, but will not mean a "sea change" in reimbursement, agency official says. Real issue is "unorganized" approach to off-label use as a whole in the U.S.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.